Abstract
First-line platinum-based chemotherapy combinations are considered standard-of-care in locally advanced and metastatic urothelial cancer. However, longterm outcomes, including disease-specific and overall survival, remain poor. In addition, a number of patients with advanced urothelial carcinoma have co-existing medical issues that preclude the use of conventional chemotherapy. Improvements in our understanding over the molecular mechanisms of urothelial cancer have led to first-generation clinical trials evaluating novel agents targeting molecular pathways that may be relevant, at least in sub-populations. Emerging information regarding outcome with agents targeting novel molecular targets in advanced urothelial cancer is discussed in this review.
Original language | English (US) |
---|---|
Pages (from-to) | 4557-4568 |
Number of pages | 12 |
Journal | Anticancer Research |
Volume | 35 |
Issue number | 9 |
State | Published - Sep 1 2015 |
Keywords
- Novel molecular targets
- Review
- Targeted therapy
- Transitional cell carcinoma
- Urothelial cancer
ASJC Scopus subject areas
- Oncology
- Cancer Research